Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment.

[1]  S. Aldhaheri,et al.  Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study , 2021, BMJ Open Respiratory Research.

[2]  D. Lynch,et al.  Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report - Executive Summary. , 2021, Chest.

[3]  N. Inui,et al.  Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival , 2020, BMC Pulmonary Medicine.

[4]  W. Travis,et al.  Diagnosis and Evaluation of Hypersensitivity Pneumonitis , 2021 .

[5]  Ling Zhao,et al.  Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study , 2020, BMJ Open.

[6]  Jonathan H. Chung,et al.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[7]  A. Prasse,et al.  Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry , 2020, European Respiratory Journal.

[8]  M. Kramer,et al.  The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis , 2020, Respiratory Research.

[9]  J. Soriano,et al.  Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry , 2019, Respiratory Research.

[10]  W. Seeger,et al.  The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis , 2018, Respiratory Research.

[11]  Z. Daniil,et al.  Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) , 2018, Respiration.

[12]  A. Warth,et al.  Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis , 2018, Respiration.

[13]  D. Lynch,et al.  Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. , 2017, The Lancet. Respiratory medicine.

[14]  G. Raghu,et al.  Interstitial Lung Disease in India. Results of a Prospective Registry , 2017, American journal of respiratory and critical care medicine.

[15]  J. Ryu.  Faculty of 1000 evaluation for An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. , 2016 .

[16]  D. Lynch,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.

[17]  Emily C. O'Brien,et al.  Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry , 2016, BMJ Open Respiratory Research.

[18]  M. Sköld,et al.  Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry , 2016, European clinical respiratory journal.

[19]  D. Lynch,et al.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.

[20]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[21]  R. Wood‐Baker,et al.  Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project , 2014, Respirology.

[22]  H. Collard,et al.  A global registry for idiopathic pulmonary fibrosis: the time is now , 2014, European Respiratory Journal.

[23]  Luca Richeldi,et al.  Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment , 2014, European Respiratory Review.

[24]  J. Behr,et al.  Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry , 2014, BMJ Open Respiratory Research.

[25]  G. Raghu,et al.  Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. , 2013, The Lancet. Respiratory medicine.

[26]  J. Behr.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[27]  E. Bagiella,et al.  Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. , 2011, American journal of respiratory and critical care medicine.

[28]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[29]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .